TrialSignal
Clinical trial intelligence report
Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03054337
Status
COMPLETED
Phase
Phase 2
Sponsor
Akebia Therapeutics
Executive brief
Investment-Ready Snapshot
The trial evaluated vadadustat, a hypoxia-inducible factor stabilizer, for treating anemia in Japanese patients with NDD-CKD. The study was randomized, double-blind, and placebo-controlled, involving 51 participants across multiple sites in Japan. The primary endpoint was the change in hemoglobin levels over 6 weeks.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03054337
Indication
Anemia
Modality
small molecule
Target
Anemia secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Intervention
Vadadustat, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.